Luis Arias, MD; and Paolo Lanzetta, MD, recently found themselves on opposite sides of the debate table regarding the value ...

DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 – – New ...

While anti-VEGF therapies remain the current standard of care, many DME patients experience suboptimal responses due to ...

DAVIO-2 for wet AMD and VERONA for DME. In the DAVIO-2 trial, patients previously treated with approximately 10 injections in ...

Group sales In the first nine months of 2025, Roche achieved sales growth of 7% (2% in CHF) to CHF 45.9 billion due to strong demand for our pharmaceutical and diagnostic products.

EyePoint (EYPT) announced details for its pivotal Phase 3 program evaluating Duravyu for the treatment of diabetic macular edema with first ...

Johns Hopkins researchers developed a digital refocusing technique for retinal imaging, enhancing image quality and reducing ...

The treatment involves inserting a tiny implant thinner than human hair under the retina. Patients then have to wear glasses ...

Today, in the New England Journal of Medicin e, researchers announced that they restored some vision to elderly patients with ...

The device helped people with an advanced form of age-related macular degeneration, which affects about 1 million people in ...

A groundbreaking European trial has shown that a new electronic eye implant, paired with augmented-reality glasses, can restore reading vision to patients blinded by geographic atrophy from dry ...

UB ophthalmologist Margaret DeAngelis leads work on the neurological condition that's the leading cause of blindness in adults over 55.